Citi lowered the firm’s price target on Arrowhead to $29 from $34 and keeps a Neutral rating on the shares. At the fiscal Q2 update, Arrowhead shared that Plozasiran’s topline data in familial chylomicronemia syndrome is expected on June 25. The firm expects the data to be competitive, but the market size is modest
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR: